122 related articles for article (PubMed ID: 22559196)
1. Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients.
March-Villalba JA; Martínez-Jabaloyas JM; Herrero MJ; Santamaría J; Aliño SF; Dasí F
Expert Opin Biol Ther; 2012 Jun; 12 Suppl 1():S69-77. PubMed ID: 22559196
[TBL] [Abstract][Full Text] [Related]
2. Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics.
March-Villalba JA; Martínez-Jabaloyas JM; Herrero MJ; Santamaria J; Aliño SF; Dasí F
PLoS One; 2012; 7(8):e43470. PubMed ID: 22916267
[TBL] [Abstract][Full Text] [Related]
3. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer.
Dasí F; Martínez-Rodes P; March JA; Santamaría J; Martínez-Javaloyas JM; Gil M; Aliño SF
Ann N Y Acad Sci; 2006 Sep; 1075():204-10. PubMed ID: 17108213
[TBL] [Abstract][Full Text] [Related]
4. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
6. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.
Deligezer U; Yaman F; Darendeliler E; Dizdar Y; Holdenrieder S; Kovancilar M; Dalay N
Clin Chim Acta; 2010 Oct; 411(19-20):1452-6. PubMed ID: 20573596
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
8. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
[TBL] [Abstract][Full Text] [Related]
9. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment.
Ferrari AC; Stone NN; Kurek R; Mulligan E; McGregor R; Stock R; Unger P; Tunn U; Kaisary A; Droller M; Hall S; Renneberg H; Livak KJ; Gallagher RE; Mandeli J
J Clin Oncol; 2006 Jul; 24(19):3081-8. PubMed ID: 16809733
[TBL] [Abstract][Full Text] [Related]
10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
11. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
12. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
14. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
de Kok JB; Verhaegh GW; Roelofs RW; Hessels D; Kiemeney LA; Aalders TW; Swinkels DW; Schalken JA
Cancer Res; 2002 May; 62(9):2695-8. PubMed ID: 11980670
[TBL] [Abstract][Full Text] [Related]
15. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
16. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease.
Terrin L; Rampazzo E; Pucciarelli S; Agostini M; Bertorelle R; Esposito G; DelBianco P; Nitti D; De Rossi A
Clin Cancer Res; 2008 Nov; 14(22):7444-51. PubMed ID: 19010861
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of tumor necrosis factor receptor superfamily member 11b polymorphism in prostate cancer.
Bao BY; Lin VC; Huang SH; Pao JB; Chang TY; Lu TL; Lan YH; Chen LM; Ting WC; Yang WH; Hsieh CJ; Huang SP
Ann Surg Oncol; 2010 Jun; 17(6):1675-81. PubMed ID: 20204532
[TBL] [Abstract][Full Text] [Related]
18. Molecular staging of pelvic surgical margins after radical prostatectomy: comparison of RT-PCR for prostate-specific antigen and telomerase activity.
Straub B; Müller M; Krause H; Goessl C; Schrader M; Heicappell R; Miller K
Oncol Rep; 2002; 9(3):545-9. PubMed ID: 11956625
[TBL] [Abstract][Full Text] [Related]
19. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491
[TBL] [Abstract][Full Text] [Related]
20. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
